ELREXFIO(elranatamab-bcmm，埃納妥單抗)by forwardhealth-userElranatamab也稱為PF-06863135，是一種B細胞成熟抗原(BCMA)靶向T細胞重定向免疫療法。BCMA在多發性骨髓瘤(MM)細胞表面高表達。Elranatamab還旨在靶向T細胞表面的CD3受體，以破壞骨髓瘤細胞。 Leave a Reply Cancel replyYour email address will not be published. Required fields are marked *Name * Email * Website Comment * Save my name, email, and website in this browser for the next time I comment.
English 
Chinese